XNCR
Closed
Xencor Inc
16.18
-0.14 (-0.86%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 16.32
Day's Range: 16.135 - 16.66
Send
sign up or login to leave a comment!
When Written:
28.55
Xencor Inc is a clinical-stage biopharmaceutical company that focuses on developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma, and allergic diseases. The company's proprietary technology platform, XmAb, enables the creation of antibodies with enhanced pharmacokinetic properties and improved effector function. Xencor's pipeline includes multiple clinical-stage programs, including XmAb14045, XmAb13676, and XmAb20717, among others. The company is headquartered in Monrovia, California, and was founded in 1997. Xencor has collaborations with several pharmaceutical companies, including Novartis, Amgen, and MorphoSys.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
28.55
Xencor Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California, USA. The company focuses on developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Xencor's proprietary XmAb technology platform enables the creation of monoclonal antibodies with enhanced effector function and improved pharmacokinetic properties.
The company's pipeline includes several candidates in clinical development for the treatment of various types of cancer, including acute myeloid leukemia, non-Hodgkin's lymphoma, and solid tumors. Xencor also has a collaboration with Novartis to develop bispecific antibodies for the treatment of cancer.
Xencor was founded in 1997 and went public in 2013. As of 2021, the company has a market capitalization of approximately $4 billion.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's pipeline includes several candidates in clinical development for the treatment of various types of cancer, including acute myeloid leukemia, non-Hodgkin's lymphoma, and solid tumors. Xencor also has a collaboration with Novartis to develop bispecific antibodies for the treatment of cancer.
Xencor was founded in 1997 and went public in 2013. As of 2021, the company has a market capitalization of approximately $4 billion.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!